Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

@article{Arndt2009VincristineAA,
  title={Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.},
  author={Carola A. S. Arndt and Julie Ann Stoner and Douglas S Hawkins and David A. Rodeberg and Andrea A. Hayes-Jordan and Charles N. Paidas and David M. Parham and Lisa A. Teot and Moody D. Wharam and John Breneman and Sarah S. Donaldson and James R. Anderson and William Meyer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 31},
  pages={5182-8}
}
PURPOSE The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristine, topotecan, and cyclophosphamide (VAC/VTC). PATIENTS AND METHODS Patients were randomly assigned to 39 weeks of VAC versus VAC/VTC; local therapy began after week 12. Patients with parameningeal RMS with intracranial… CONTINUE READING
58 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…